All In Biotech

Drug Trial Radar · NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,263

Actual

Start

Aug 27, 2018

Primary completion

Mar 27, 2022

Study completion Mar 27, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • DapagliflozinDrug

    10 mg tablets given once daily, per oral use.

  • PlaceboDrug

    Placebo matching dapagliflozin 10 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.Time frame: Up to 42.1 months
  2. Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% SubpopulationTime frame: Up to 42.1 months

Locations

348 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairhope, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Loma Linda, California

  • Research Site

    Los Angeles, California

  • Research Site

    Stamford, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Naples, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Saint Augustine, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Gurnee, Illinois

  • Research Site

    Anderson, Indiana

  • Research Site

    Munster, Indiana

  • Research Site

    Louisville, Kentucky

  • Research Site

    Hammond, Louisiana

  • Research Site

    Houma, Louisiana

  • Research Site

    Monroe, Louisiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Bay City, Michigan

  • Research Site

    Flint, Michigan

  • Research Site

    Flint, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Rochester, Minnesota

  • Research Site

    Saint Paul, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Great Falls, Montana

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Lebanon, New Hampshire

Showing 40 of 348 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.